Journal of Clinical Oncology
Articles in this Issue
Efficacy of bintrafusp alfa (M7824) in patients with gastrointestinal tumors: A meta-analysis.
e16077 Background: This meta-analysis aims to evaluate the efficacy and safety of Bintrafusp Alfa (M7824) in patients with gastrointestinal tumors....
Efficacy and safety of triple oral metronomic chemotherapy in patients with advanced esophageal squamous cell carcinoma.
e16043 Background: Patients with advanced esophageal squamous cell carcinoma (ESCC) have dismal survival outcomes post-progression on standard first-line...
Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort.
5591 Background: The FRα-directed antibody-drug conjugate mirvetuximab soravtansine-gynx (MIRV) provides survival benefit vs investigator’s choice chemoth...
Barriers to palliative care access in patients with brain metastases: A comprehensive national study.
12095 Background: Palliative care (PC) improves the quality of life for patients with advanced cancer, including those with brain metastases (BM). Despite...
Concurrent trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer: Assessing the efficacy.
e13000 Background: Metastatic breast cancer, particularly that which expresses the HER2 receptor, poses a significant therapeutic challenge in oncology, o...
Understanding and addressing unmet needs in colorectal cancer: Findings from the Colorectal Cancer Alliance’s Patient and Survivor survey.
3576 Background: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Desp...
Genomic landscape of NSCLC with no targetable driver mutation among different races: An exploratory analysis of the AACR Project GENIE Database.
8041 Background: Non-small cell lung cancer (NSCLC) is the most prevalent subtype of lung cancer, and it has been historically associated with poor progno...
Early palliative care, intensity of end-of-life care, and their impact on overall survival in cancer patients: A real-world study.
12065 Background: Early palliative care (EPC) and reduced aggressive end-of-life (EOL) interventions improve quality of li...
Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small cell lung cancer following definitive chemoradiation.
1580 Background: Since the approval of immunotherapy (IO) for maintenance therapy in stage III non-small cell lung cancer (NSCLC) in 2018, its use has exp...
Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC).
5513 Background: Preclinical studies have demonstrated synergism with simultaneous inhibition of the estrogen receptor (ER), CDK4/6 and PI3K pathways. Met...
DNA methylation signatures as predictive biomarkers for chemotherapy (CT) resistance and survival in pancreatic ductal adenocarcinoma (PDA).
4151 Background: Predicting innate treatment resistance to traditional CT in PDA can optimize therapeutic strategies and improve patient outcomes. This st...
Real-world analysis of folate receptor alpha (FRα; FOLR1) expression in pan-tumor samples from over 6000 patients in the US.
5568 Background: FRα is overexpressed in several cancers, including ovarian and endometrial. The FRα-targeted antibody-drug conjugate mirvetuximab soravta...
Efficacy and safety of trastuzumab deruxtecan in HR-negative HER2-low advanced breast cancer: A real-world, retrospective study.
e15019 Background: Trastuzumab deruxtecan (T-DXd) demonstrated promising efficacy in patients with HER2-low metastatic breast cancer (mBC), while most pat...
Appropriate treatment for stage 1 and 2 HER 2 positive and triple-negative breast cancer by immigration status in Ontario, Canada.
e12511 Background: This study explored the appropriateness of treatment received for stages 1 and 2 HER2-positive and triple-negative (TNBC) breast cancer...
Comparing <i>BRCA1/2</i> copy number loss assessment in circulating tumor DNA to tissue in advanced solid cancers.
e14545 Background: Next generation sequencing (NGS) identifies genomic alterations in DNA obtained from tissue biopsies and/or blood [circulating tumor (c...
Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).
7023 Background: Axi-cel is an autologous chimeric antigen receptor (CAR) T-cell therapy approved for adults with R/R LBCL after ≥ 1 prior line of therapy...
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
4503 Background: In the phase 3 NIAGARA trial (NCT03732677) of patients (pts) with cisplatin-eligible MIBC, addition of perioperative D to neoadjuvant che...
Epidemiology, survival outcomes, and impact of treatment modalities in rectal squamous cell carcinoma: A SEER database study.
e15680 Background: Rectal cancers represent 35% of colorectal cancers; 90% are adenocarcinomas, while squamous cell carcinoma accounts for only 0.3% of th...
DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.
7533 Background: In DREAMM-8 (NCT04484623), BPd demonstrated a significant improvement in the risk of progression or death vs PVd in patients (pts) with R...
Racial differences in cardiovascular outcomes among cancer patients receiving immune checkpoint inhibitors.
1613 Background: Immune checkpoint inhibitors (ICIs) increase the risk of major adverse cardiovascular events (MACE). We aimed to evaluate disparities in...
A phase II study to evaluate the efficacy and safety of fruquintinib combined with envafolimab in patients with advanced or unresectable locally advanced osteosarcoma and soft tissue sarcoma.
e23506 Background: There is an urgent clinical need for second-line therapy to improve survival in advanced osteosarcoma (OS) and soft tissue sarcoma (STS...
Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated non-small cell lung cancer with brain metastases.
8556 Background: Osimertinib has demonstrated efficacy in managing brain metastases in EGFR-mutated non-small cell lung cancer (NSCLC). However, the optim...
Pathogenic germline variants in breast cancer patients associated with different HER2 expression levels.
e12543 Background: Germline pathogenic/likely pathogenic variants (PV) were evaluated in 530 Chinese breast cancer patients and 98 patients with atypical...
Analysis of trends in race and gender disparities in the incidence of pheochromocytoma from 2000 to 2020.
e22545 Background: Pheochromocytoma is a rare tumor of the adrenal gland with an estimated incidence of 2-8/million. The trends of incidence of pheochromo...
Genomic predictive biomarkers of anti-EGFR resistance in EGFR-mutated non-small-cell lung cancer: Impact of classical mutations, comutations and secondary CNVs.
e20670 Background: Non-small-cell lung cancer (NSCLC) with EGFR mutations, particularly in exons 19 and 21, has shown variable res...